You are here

  • Home
  • Archive
  • Volume 107, Issue 23
  • Response to: Correspondence on “Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure” by Yalta et al

Article Text

Article menu
Download PDFPDF
Correspondence
Response to: Correspondence on “Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure” by Yalta et al
  1. Shruti S Joshi1,
  2. Trisha Singh1,
  3. Jagdeep Singh2,
  4. David E Newby1
  1. 1 Centre for Cardiovascular Science, University of Edinburgh Division of Clinical and Surgical Sciences, Edinburgh, UK
  2. 2 Department of Cardiology, NHS Lothian, Edinburgh, UK
  1. Correspondence to Dr Shruti S Joshi, Centre for Cardiovascular Sciences, University of Edinburgh Division of Clinical and Surgical Sciences, Edinburgh, UK; sjoshi{at}ed.ac.uk

https://doi.org/10.1136/heartjnl-2021-320174

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The Authors’ reply

    We would like to thank Yalta et al 1 for their interest in our review. We share their enthusiasm for the potential metabolic benefits of sodium-glucose co-transporter 2 (SGLT-2) inhibition.

    We agree with Yalta et al that in patients with type 2 diabetes or heart failure, there is dysregulated fatty acid oxidation and impaired glucose uptake causing myocardial dysfunction. In this setting of restricted fuel selection and low energetic reserve, ketone bodies are a super-fuel producing Adenosine triphosphate (ATP) more efficiently than free fatty acids or glucose, which usually serve as fuels for …

    View Full Text

    Footnotes

    • Contributors SSJ drafted the initial manuscript with contributions from all authors.

    • Funding The authors are supported by British Heart Foundation (SJ, RE/18/5/3 and FS/CRTF/20/24087; TS RE/18/5/3; DEN, CH/09/002, RG16/10/3, RE18/5/3), Medical Research Council (TS, MR/T029153/1), Wellcome Trust (DEN, WT103782AIA) and an investigator initiated award from AstraZeneca (SJ, SER-19-20118)

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles